On November 12, Genmab A/S fell 4.12% in Pre-Market Trading, trading at $51.65/share, with turnover of $8.1664 million.
The latest move followed a pullback after earlier catalysts had already driven a sharp re-rating, with recent reporting indicating that prior strength tied to Genmab A/S's quarterly earnings beat and Petosemtamab phase 3 progress was cooling.
Previously, the company reported third-quarter EPS of $5.51, well above the $3.59 consensus estimate, while sales of $1.187 billion were slightly below the $1.194 billion estimate, and it maintained full-year guidance. In addition, Petosemtamab plus pembrolizumab met both primary endpoints in the phase 3 LiGeR-HN1 study in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma, with the combination reducing the risk of death by 50% versus pembrolizumab alone. The current weakness appears consistent with fading event-driven momentum after those gains.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)